FDA Leaders Name Longevity a Priority at ARDD
Key claim: At ARDD in Boston, FDA senior officials announced plans to include aging in the agency’s regulatory science agenda and discussed how longevity therapies could be regulated.
Abstract
At a panel in Boston, senior officials announced plans to include aging in the agency’s regulatory science agenda and discussed how therapies […]
Why this matters
A senior FDA signal that aging will be written into the agency’s regulatory science agenda is the kind of institutional move that reshapes which longevity therapies ever reach a label — distinct from any science advancing. Tracked here as a trend signal (expert-opinion tier, news report), it marks when geroscience moved from academic conference talk toward a plausible regulatory pathway, while the underlying evidence base for most longevity interventions in this area has not changed.